Chinese Infectious Disease Drugs Market Report 2015-2016 &

New Post Public Reply Private Reply Replies (0) Message Board

News Desk 2018

Mar 27, 2017 at 6:00 AM 181

Chinese Infectious Disease Drugs Market Report 2015-2016 & 2021: Research into the $61.7 Billion Industry with 100+ Company Profiles

Dublin, March 27, 2017 (GLOBE NEWSWIRE) -- Research and Markets has announced the addition of the "Infectious Disease Drugs: The Chinese Market" report to their offering. The Chinese Infectious Disease Drugs Market Should Reach $61.7 Billion by 2021, CAGR of 13.9%

The scope of the report includes infectious disease drugs applications, industries, markets and companies in China. The markets for infectious disease drugs are given for the years 2015, 2016 and 2021.

Report Includes - An overview of the Chinese market for infectious disease drugs. - Analyses of global market trends, with data from 2015 and 2016, and projections of compound annual growth rates (CAGRs) through 2021. - Discussion of the increasing concern regarding antibiotic-resistant organisms and their sometimes-fatal effects on humans. - Examination of technological developments, future trends, and emerging opportunities. - Assessments of the current state of infectious diseases on a global basis, broken down by type of disease (i.e., bacterial, viral, parasitic, and fungal) and appropriate treatments, both current and anticipated, and by geographic region. - Profiles of major players in the field of infectious disease treatments. The report covers the Chinese market for both communicable and noncommunicable infectious disease drugs. In this report, communicable infectious diseases only refer to the 39 statutory communicable diseases stated by the National Health and Family Planning Commission of the People's Republic of China (NHFPC). They include viral hepatitis, pulmonary tuberculosis, syphilis, bacillary/amebic dysentery, gonorrhea, scarlet fever, brucellosis, acquired immunodeficiency syndrome (AIDS), hand-foot-and-mouth disease, infectious diarrhea, influenza, and epidemic parotitis. In this report, China is referred to as Mainland China. It does not include Hong Kong, Macao and Taiwan. Mainland China has a total of 31 province-level regions, including 22 provinces, four province-level municipalities (cities) and five province-level autonomous regions. Important geographic markets will be discussed, including Beijing, Shanghai, Guangdong and others. More than 100 Chinese companies in the infectious disease drug industry are profiled in this report. Key Topics Covered: 1: Introduction 2: Summary - Largest And Fastest-Growing Markets - Laws, Regulations And Targets 3: The Chinese Drug Market - Chinese Drug Market By Sales Channels - Chinese Drug Market By Drug Type 4: Chinese Infectious Disease Drug Market By Disease - Most Common 39 Communicable Diseases - Other Infectious Diseases 5: Chinese Infectious Disease Drug Market By Products - Top 30 And Top 100 Infectious Disease Drugs In China 6: Chinese Infectious Disease Drugs By Producers - Chinese Homegrown Drugmakers - Foreign Drug Markets In The Chinese Market 7: The Chinese Infectious Disease Drug Market By Sales Channels - Chinese Infectious Disease Drugs Retail Market - Chinese Hospital Market For Infectious Disease Drugs 8: Chinese Infectious Disease Drug Market By Geography - Chinese Geography - Chinese Infectious Disease Drug Market By Geography - Chinese Infectious Drug Market By Province 9: Industry Structure And Market Strategies - Drugmakers - Drug Wholesalers - Drug Retailers - Exclusive Distributors - Hospitals - Retailers - End Consumers 10: Company Profiles - Anhui Biochem United Pharmaceutical Co. Ltd. - Bayer China Ltd. - Beijing Tong Ren Tang - Bristol-Myers Squibb (China) Investment Co. Ltd. - Chiatai Tianqing Pharmaceutical Group Co. Ltd. - China Pharmaceutical University Pharmaceutical Co. Ltd. (Cpu-Pharma) - Chongqing Kerui Pharmaceutical Co. Ltd. - Chongqing Lummy Pharmaceutical Co. Ltd. - Dashenlin - Dawnrays Pharmaceutical (Holdings) Ltd. - Ebang Pharmaceutical - Fujian Cosunter Pharmaceutical Co. Ltd. - Furen Huaiqingtang Pharmaceutical Co. Ltd. - Gsk China - Guangzhou Baiyunshan Pharmaceutical Holding Co. Ltd. - Guoda Drugstore - Harbin Pharmaceutical Group Holding Co. Ltd. - Hunan Qianjin Xiangjiang Pharmaceutical Industry Co. Ltd. - Hunan Xinhui Pharmaceutical Co. Ltd. - Jiangsu Wuzhong Pharmaceutical Group Corporation - Kelun Industry Group & Sichuan Kelun Pharmaceutical Co. Ltd. - Luoxin Pharmaceutical - Medfron - Msd China - North China Pharmaceutical Group - Panbiotic - Pfizer China - Qilu Pharmaceutical Co. Ltd. - Qingfeng Pharmaceutical Group - Reyoung Pharmaceutical Co. Ltd. - Roche China - Rundu Pharma - Shandong Lukang Pharmaceutical Co. Ltd. - Shandong Runze Pharmaceutical Co. Ltd. - Sumitomo Pharmaceuticals (Suzhou) Co. Ltd. - Tungshun Pharmaceutical - Waterstone Pharmaceuticals - Yongning Pharma - Youcare Pharmaceutical Group Co. Ltd. - Yung Shin Pharm. Ind. (Kunshan) Co. Ltd. - Zhejiang Hisun Pharmaceutical Co. Ltd. - Zhejiang Medicine Co. Ltd. - Zhijun Pharmaceutical Co. Ltd. - Zhuhai United Laboratories Co. Ltd. 11: Appendix For more information about this report visit http://www.researchandmarkets.com/research/p9pn2z/infectious

CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Related Topics: Infectious Diseases Drugs

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Fibocom LTE Modules Test Drive Satellite Connectivity

Boosting IoT with Satellite Connectivity Here's a good one for folks watching the edge of wireless innovation. Fibocom's LTE Cat.1 bis modules, the LE270-EU and LE271-GL, just stretched their legs in New Zealand, connecting seamlessly with SpaceX's Direct to Cell (DTC) satellite system. No fancy hardware swaps, just standard firmware strutting its stuff across satellite...

JNJ's Dual-Antigen Therapy Shows Promise in Prostate Cancer

Exploring a New Front in Cancer Treatment Johnson & Johnson (NYSE: JNJ) just dropped a bombshell at the Society for Immunotherapy of Cancer (SITC) 2026 Annual Meeting, unveiling data that could reshape prostate cancer care. Their pioneering combo of pasritamig and JNJ-9401, a dual-antigen-targeted therapy, has the scientific community buzzing. Yeah, it's just Phase 1 baby...

ASTS Faces Class Action; Investors Beware of Pitfalls

Securities Fraud Allegations Hit AST SpaceMobile Days like this remind me why we keep our eyes peeled in the stock game—AST SpaceMobile (NASDAQ: ASTS) is tangled in a web of legal drama, and it's something you can't brush off with a shrug. Class action lawsuits for securities fraud? That's like finding out the foundation's shaky beneath a skyscraper. If you've got skin...

MWC26 Doha: Bridging Standards for MENA's Future

MWC26 Doha Launches with a Connectivity Mission Forget corporate boardrooms; the real action this week is unfolding in Doha's bustling exhibition halls. Kicked off with the fanfare you'd expect from such a key event, MWC26 Doha has drawn a crowd that's got both tech geeks and policy wonks nodding with interest. This ain’t your average trade show: it’s the melting pot...

Cleaner Air in Bedroom May Stabilize Blood Sugar Levels

Imagine a world where simply sleeping in cleaner air could affect your blood sugar. Seems far-fetched, I know. But that's where we're at with this new study out of NYU Langone Health. They're talking about using plain ol' portable air filters to help steady blood sugar levels for folks dealing with prediabetes. Turns out a cleaner bedroom might just hold the key to taming...

Novo's Semaglutide Shows Promise in MASH Study

Semaglutide, a name on the lips of many investors looking for breakthroughs, is making waves again. This time, the stir comes from recent findings in the MASH field, and it's got folks in white coats quite excited. Revolutionary Results from Novo Novo Nordisk has announced promising results from their phase 3 ESSENCE trial that looks into semaglutide's effects on a...

Allergan Aesthetics Study Shows Rising Patient Satisfaction

Enhanced Patient Satisfaction with Aesthetic Treatments Dive into the latest studies from Allergan Aesthetics—AbbVie's heavyweight in the beauty battleground. If you've got an ounce of optimism left in this market, their recent findings might just lift your spirits. Phase 4 studies, namely HARMONY IN DIVERSITY and HALO, are showing highly positive results among patients...

D-Wave's Legal Trouble: Securities Fraud Suit Looms

A Looming Legal Storm for D-Wave Investors Call it another day, another legal tangle in the investing world. This time, it's D-Wave Quantum Inc. (NASDAQ: QBTS) on the receiving end of a securities fraud class action lawsuit. Yeah, those fancy quantum computers they're pushing didn't predict this one coming. The legal arena is getting ready for a bout, and if you've got...

Webull Faces Class Action Suit: Key Deadlines Loom

The Clock is Ticking for Webull Investors If anyone's got a Webull stake, listen up! You’ve got a deadline that's staring you in the face: December 7, 2026. This is when you need to throw your hat in the ring to be a lead plaintiff in the Webull Corporation class action. We're talking securities fraud, folks, with allegations flying that would make your head spin....

Intelligent Communication Forum Eyes Global Ecosystem Shift

China's Grand Vision for Intelligent Communication You know what they say about big ideas—they start in the most bustling of places. And here we are in Wuxi, a city's pulse pounding with ambition, hosting the 2026 China International Intelligent Communication Forum. Picture it: From November 8th to 10th, movers, shakers, and visionaries are scribbling new blueprints for...